Efficacy and tolerability of simvastatin (MK-733)
- 1 October 1989
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 87, S39-S43
- https://doi.org/10.1016/s0002-9343(89)80597-2
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- CHOLESTEROL SYNTHESIS INHIBITORS IN HYPERLIPIDAEMIAThe Lancet, 1988
- Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein BAtherosclerosis, 1988
- Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemiaAtherosclerosis, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1987
- Current pharmacologic treatment of elevated serum cholesterol.Circulation, 1987
- Therapeutic Response to Lovastatin (Mevinolin) in Nonfamilial HypercholesterolemiaJAMA, 1986
- EFFECTS OF SYNVINOLIN (MK-733) ON PLASMA LIPIDS IN FAMILIAL HYPERCHOLESTEROLAEMIAThe Lancet, 1986
- Preliminary report: Treatment of type 3 hyperlipoproteinemia with mevinolinMetabolism, 1986
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984